Sardar Moodliar Road,
, Rasta Peth, Pune, Maharashtra - 411011
Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Shona Milon Nag and her staff know how they are doing and how they can improve their services.
How was your experience with Dr. Shona Milon Nag?
Help other patients, and let the doctor know how she's doing
GSK-ERI award for ethnic research in breast cancer awarded to Dr Shona Nag, Jehangir Hospital and Dr Sudeep Gupta, Tata Memorial Hospital in Dec 2009 for project on “Distribution of clinical subtypes and associated risk factors for breast cancer in urban Indian women”
ISCR award 2010 for best research site – Principal Investigator Dr Shona Nag and JCDC in October 2010, Bangalore
Hepatitis B Viral Infection in ALL Nag S., Pai S. K., Advani S. H.;. Indian J. Haem. And Blood Transfusion, 1995; 13:150-3.
Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial: C1-05 Journal of Thoracic Oncology. 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007. 2(8) Supplement 4:S360, August 2007.
Parikh, Purvish M. 1; Wang, Yenyun 2; Ranade, A A. 3; Vaid, A K. 4; Advani, S H. 5; Raghunadharao, D 6; Nag, S 7; Madhavan, J P. 8; Varadhachary, Atul 9Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With CelecoxibLuc Yves Dirix, Jorge Ignacio, Shona Nag, Poonamally Bapsy, Henry Gomez, Digumarti
Raghunadharao, Robert Paridaens, Stephen Jones, Silvia Falcon, Marina Carpentieri, Antonello Abbattista, Jean-Pierre Lobelle Journal of Clinical Oncology Mar 10 2008: 1253-1259
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profilingP K Julka1, R T Chacko2, S Nag3, R Parshad1, A Nair2, D S Oh4, Z Hu4, C B Koppiker3, S Nair2, R Dawar1, N Dhindsa5, I D Miller6, D Ma7, B Lin7, B Awasthy8 and C M PerouBritish Journal of Cancer (2008) 98, 1327–1335. Published online 1 April 2008
Clinical Experience with Gefitinib in Indian PatientsParikh, Purvish MD *; Chang, Alex Yuang-Chi BM +; Nag, Shona MD ++; Digumarti, Raghunadharao MD [S]; Bhattacharyya, Gouri Shankar MD |; Doval, Dinesh Chandra MD [P]; Babu, Govind MD #; Chacko, Raju Titus MD **; Advani, Suresh MD ++;
Ranade, Anantbhushan MD ++++; Aggarwal, Shyam MD [S][S]; Jagannathan, Ramesh MD ||; Hargreaves, Laura MSc [P][P]; Thatcher, Nick PhD ##Journal of Thoracic Oncology. 3(4):380-385, April 2008
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast CancerHenry L. Gomez, Dinesh C. Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X. Franco, Louis W.C. Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H. Stein, George W. Sledge Journal of Clinical Oncology Jun 20 2008: 2999-3005
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentKathy S. Albain, Shona M. Nag, German Calderillo-Ruiz, Johann P. Jordaan, Antonio C. Llombart, Anna Pluzanska, Janusz Rolski, Allen S. Melemed, Jose M. Reyes-Vidal, Jagdev S. Sekhon, Lorinda Simms, and Joyce O'Shaughnessy Journal of Clinical Oncology Aug 20 2008: 3950–3957
Optimizing management of cancer related anemia.K Prabhash, S.Nag, S Patil, PM Parikh.